FDA Approves Grifols Malaria Blood Screening Assay

Why It Matters

By enabling highly sensitive, automated malaria screening, the assay strengthens blood‑safety programs and reduces the risk of transfusion‑transmitted infection, a critical concern for hospitals and blood centers.

Key Takeaways

• Procleix Plasmodium assay detects five malaria species in donor blood
• FDA clearance enables use on existing Procleix Panther platforms
• Nucleic acid test improves sensitivity over traditional microscopy
• Early malaria detection reduces transfusion‑transmitted infection risk
• Assay supports compliance with FDA’s blood safety guidelines

Pulse Analysis

Malaria remains a global health challenge, with an estimated 200 million cases and hundreds of thousands of deaths each year. While most infections occur in endemic regions, travelers and migrants can introduce the parasite into non‑endemic countries, creating a hidden threat to blood supplies. Historically, blood banks have relied on donor questionnaires and microscopy, both of which miss low‑level parasitemia and can delay detection. The FDA’s recent approval of a molecular test reflects a broader shift toward nucleic‑acid technologies that can uncover subclinical infections before they reach the transfusion threshold.

Grifols’ Procleix Plasmodium assay leverages magnetic‑based target capture and transcription‑mediated amplification to amplify ribosomal RNA from *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale* and *P. knowlesi*. The chemiluminescent readout delivers results in under an hour, and because the assay runs on the widely deployed Procleix Panther system, laboratories can integrate malaria screening without additional capital outlay. Compared with microscopy, the assay’s limit of detection is orders of magnitude lower, translating into a higher safety margin for recipients of red‑cell and platelet products.

The clearance also reshapes the competitive landscape for blood‑screening diagnostics. With Roche, Abbott and other giants already offering nucleic‑acid tests for viruses, Grifols now positions itself as a specialist in parasitic screening, opening opportunities for bundled panels that cover both viral and parasitic threats. Blood centers can now meet FDA guidance on transfusion‑transmitted malaria more efficiently, potentially expanding donor pools in regions with higher travel exposure. As regulatory bodies worldwide observe the U.S. move, similar approvals may follow, accelerating global adoption of molecular malaria testing and reinforcing the safety net for millions of transfusion recipients.